A Pipeline for Automated Voxel Dosimetry: Application in Patients with Multi-SPECT/CT Imaging After 177Lu-Peptide Receptor Radionuclide Therapy

被引:18
|
作者
Dewaraja, Yuni K. [1 ]
Mirando, David M. [2 ]
Peterson, Avery B. [1 ,3 ]
Niedbala, Jeremy [1 ]
Millet, John D. [1 ]
Mikell, Justin K. [4 ]
Frey, Kirk A. [1 ]
Wong, Ka Kit [1 ]
Wilderman, Scott J. [1 ]
Nelson, Aaron S. [2 ]
机构
[1] Univ Michigan, Dept Radiol, Ann Arbor, MI 48104 USA
[2] MIM Software Inc, Cleveland, OH USA
[3] Wayne State Univ, Dept Radiat Oncol, Detroit, MI USA
[4] Univ Michigan, Radiat Oncol, Ann Arbor, MI USA
关键词
KIDNEY DOSIMETRY; IMAGES;
D O I
10.2967/jnumed.121.263738
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Patient-specific dosimetry in radiopharmaceutical therapy (RPT) is impeded by the lack of tools that are accurate and practical for the clinic. Our aims were to construct and test an integrated voxel-level pipeline that automates key components (organ segmentation, registration, dose-rate estimation, and curve fitting) of the RPT dosimetry process and then to use it to report patient-specific dosimetry in Lu-177-DOTATATE therapy. Methods: An integrated workflow that automates the entire dosimetry process, except tumor segmentation, was constructed. First, convolutional neural networks (CNNs) are used to automatically segment organs on the CT portion of one posttherapy SPECT/CT scan. Second, local contour intensity-based SPECT-SPECT alignment results in volume-of-interest propagation to other time points. Third, dose rate is estimated by explicit Monte Carlo (MC) radiation transport using the fast, Dose Planning Method code. Fourth, the optimal function for dose-rate fitting is automatically selected for each voxel. When reporting mean dose, we apply partial-volume correction, and uncertainty is estimated by an empiric approach of perturbing segmentations. Results: The workflow was used with 4-time-point Lu-177 SPECT/CT imaging data from 20 patients with 77 neuroendocrine tumors, segmented by a radiologist. CNN-defined kidneys resulted in high Dice values (0.91-0.94) and only small differences (2%-5%) in mean dose when compared with manual segmentation. Contour intensity-based registration led to visually enhanced alignment, and the voxel-level fitting had high R-2 values. Across patients, dosimetry results were highly variable; for example, the average of the mean absorbed dose (Gy/GBq) was 3.2 (range, 0.2-10.4) for lesions, 0.49 (range, 0.24-1.02) for left kidney, 0.54 (range, 0.31-1.07) for right kidney, and 0.51 (range, 0.27-1.04) for healthy liver. Patient results further demonstrated the high variability in the number of cycles needed to deliver hypothetical threshold absorbed doses of 23 Gy to kidney and 100 Gy to tumor. The uncertainty in mean dose, attributable to variability in segmentation, averaged 6% (range, 3%-17%) for organs and 10% (range, 3%-37%) for lesions. For a typical patient, the time for the entire process was about 25 min (similar to 2 min manual time) on a desktop computer, including time for CNN organ segmentation, coregistration, MC dosimetry, and voxel curve fitting. Conclusion: A pipeline integrating novel tools that are fast and automated provides the capacity for clinical translation of dosimetry-guided RPT.
引用
收藏
页码:1665 / 1672
页数:8
相关论文
共 50 条
  • [31] Patient-Specific Dosimetry of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy with High Activities
    Beykan, S.
    Eberlein, U.
    Werner, R. A.
    Lapa, C.
    Buck, A. K.
    Kudlich, T.
    Lassmann, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S33 - S33
  • [32] An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging
    Jackson, Price A.
    Beauregard, Jean-Mathieu
    Hofman, Michael S.
    Kron, Tomas
    Hogg, Annette
    Hicks, Rodney J.
    MEDICAL PHYSICS, 2013, 40 (11)
  • [33] Peptide Receptor Radionuclide Therapy with Lu-177 DOTATATE in patients with somatostatin receptor positive tumours
    Kamaleshwaran, K.
    Sudhakar, N.
    Paulvannan, S.
    Vysakh, M.
    Shinto, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S722 - S722
  • [34] Does dosimetry predict the haematological toxicity after Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-Tyr3-octreotate?
    Konijnenberg, M. W.
    Krenning, E. P.
    Cock, J. Boesen-De
    Erion, J. L.
    Kooij, P. P. M.
    Kwekkeboom, D. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S280 - S281
  • [35] Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
    Staanum, Peter Frohlich
    Frellsen, Anders Floor
    Olesen, Marie Louise
    Iversen, Peter
    Arveschoug, Anne Kirstine
    EJNMMI PHYSICS, 2021, 8 (01)
  • [36] Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
    Peter Frøhlich Staanum
    Anders Floor Frellsen
    Marie Louise Olesen
    Peter Iversen
    Anne Kirstine Arveschoug
    EJNMMI Physics, 8
  • [37] Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
    Wehrmann, Christiane
    Senftleben, Stefan
    Zachert, Carolin
    Mueller, Dirk
    Baum, Richard P.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (03) : 406 - 416
  • [38] Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival
    Loeser, Anastassia
    Schwarzenboeck, Sarah M.
    Heuschkel, Martin
    Willenberg, Holger S.
    Krause, Bernd J.
    Kurth, Jens
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (03) : 236 - 246
  • [39] A 10-Year Evolution of Patient Dosimetry for Lu-177 Dotatate Peptide Receptor Radionuclide Therapy (PRRT)
    Ross, Erin
    Ram, Lydia
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [40] Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Gupta, Santosh K.
    Singla, Suhas
    Bal, Chandrasekhar
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (09) : 593 - 599